L
Lihteh Wu
Researcher at University of Illinois at Chicago
Publications - 117
Citations - 3485
Lihteh Wu is an academic researcher from University of Illinois at Chicago. The author has contributed to research in topics: Visual acuity & Diabetic retinopathy. The author has an hindex of 29, co-authored 96 publications receiving 3010 citations.
Papers
More filters
Journal ArticleDOI
Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Lihteh Wu,Maria Ana Martinez-Castellanos,Hugo Quiroz-Mercado,J. Fernando Arevalo,Maria H. Berrocal,Michel Eid Farah,Mauricio Maia,Jose A. Roca,Francisco Rodríguez +8 more
TL;DR: Repeated intravitreal injections of either 1.25 mg or 2.5 mg of bevacizumab appears to be safe and well tolerated during the 1st year despite the limited follow-up, according to this retrospective, multicenter, open label, uncontrolled interventional case series.
Journal ArticleDOI
Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
J. Fernando Arevalo,Jans Fromow-Guerra,Hugo Quiroz-Mercado,Juan G. Sanchez,Lihteh Wu,Mauricio Maia,Maria H. Berrocal,A. Solis-Vivanco,Michel Eid Farah +8 more
TL;DR: Primary intravitreal bevacizumab at doses of 1.25 to 2.5 mg seem to provide stability or improvement in VA, OCT, and FA in DME at 6 months, and results appear promising.
Journal ArticleDOI
Classification of diabetic retinopathy and diabetic macular edema
TL;DR: The purpose of the current paper is to review the classification of DR with a special emphasis on the International Clinical Disease Severity Scale for DR, based on clinical examination and applying the Early Treatment of Diabetic Retinopathy Study 4:2:1 rule.
Journal ArticleDOI
Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema: The Pan-American Collaborative Retina Study Group at 24 Months
J. Fernando Arevalo,Juan G. Sanchez,Lihteh Wu,Mauricio Maia,Arturo Alezzandrini,Miguel Brito,Sergio Bonafonte,Silvio Lujan,Manuel Díaz-Llopis,Natalia Restrepo,Francisco Rodríguez,Patricia Udaondo-Mirete +11 more
TL;DR: Primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or improvement in BCVA, OCT, and FA in patients with diffuse diabetic macular edema at 24 months, but results show no evident difference between IVB in patients treated with at least 1 intravit real bevacizumab.
Journal ArticleDOI
Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up
J.F. Arevalo,Lihteh Wu,Juan G. Sanchez,Mauricio Maia,Mario Saravia,C. F. Fernandez,Teodoro Evans +6 more
TL;DR: In this article, the effects of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR) were studied.